Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group.

Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. Review.

PMID:
19020545
2.

Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma.

Kang SY, Suh JT, Lee HJ, Yoon HJ, Lee WI.

Ann Hematol. 2005 Sep;84(9):588-93. Epub 2005 May 10.

PMID:
15883850
3.

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.

Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA.

Clin Chem. 2005 May;51(5):878-81. Epub 2005 Mar 17.

5.

Use of interval-specific likelihood ratios improves clinical interpretation of serum FLC results for the diagnosis of malignant plasma cell disorders.

Vermeersch P, Vercammen M, Holvoet A, Vande Broek I, Delforge M, Bossuyt X.

Clin Chim Acta. 2009 Dec;410(1-2):54-8. doi: 10.1016/j.cca.2009.09.021. Epub 2009 Sep 22. Erratum in: Clin Chim Acta. 2010 Apr 2;411(7-8):613. Broeck, Isabelle Vande [corrected to Vande Broek, Isabelle].

PMID:
19778527
6.

The evolving use of serum free light chain assays in haematology.

Pratt G.

Br J Haematol. 2008 May;141(4):413-22. doi: 10.1111/j.1365-2141.2008.07079.x. Epub 2008 Mar 3. Review.

PMID:
18318757
7.

[Progress in the management of multiple myeloma introduced by serum free light chain measurement].

Fuchida S, Shimazaki C.

Nihon Rinsho. 2011 Dec;69(12):2267-73. Japanese.

PMID:
22242331
8.

Quantitative serum free light chain assay in the diagnostic evaluation of AL amyloidosis.

Akar H, Seldin DC, Magnani B, O'Hara C, Berk JL, Schoonmaker C, Cabral H, Dember LM, Sanchorawala V, Connors LH, Falk RH, Skinner M.

Amyloid. 2005 Dec;12(4):210-5.

PMID:
16399645
9.

Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine.

Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, Birtwistle J, Plant T, Afzal Z, Jefferis R, Drayson MT.

J Immunol Methods. 2013 May 31;391(1-2):1-13. doi: 10.1016/j.jim.2013.01.014. Epub 2013 Feb 4.

10.

Serum free light chains for monitoring multiple myeloma.

Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR.

Br J Haematol. 2004 Aug;126(3):348-54.

PMID:
15257706
11.
12.

Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.

Graziani MS, Merlini G.

Expert Rev Mol Diagn. 2014 Jan;14(1):55-66. doi: 10.1586/14737159.2014.864557. Epub 2013 Nov 28. Review.

PMID:
24308339
13.
14.

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases.

Tate JR, Mollee P, Dimeski G, Carter AC, Gill D.

Clin Chim Acta. 2007 Feb;376(1-2):30-6. Epub 2006 Jul 14.

PMID:
16945362
15.

Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.

Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G.

Clin Chem. 2009 Mar;55(3):499-504. doi: 10.1373/clinchem.2008.117143. Epub 2009 Jan 8.

16.

Establishment and validation of serum free light chain reference intervals in an ethnic Chinese population.

Liang YF, Chen WM, Wang QT, Zhai YH, Yang YJ, Liu JY, Levoguer A, Sun WH.

Clin Lab. 2014;60(2):193-8.

PMID:
24660530
17.

Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G.

BMC Nephrol. 2008 Sep 22;9:11. doi: 10.1186/1471-2369-9-11.

18.

Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.

Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, Sakashita K, Koike K, Ikeda S.

Intern Med. 2005 May;44(5):428-33.

19.

Complementarily of urine analysis and serum free light chain assay for assessing response treatment response: illustrated by three case examples.

Levinson SS.

Clin Chim Acta. 2011 Nov 20;412(23-24):2206-10. doi: 10.1016/j.cca.2011.08.012. Epub 2011 Aug 16.

PMID:
21864518
20.

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.

Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Bradwell AR, Buttkereit U, Opalka B, Flasshove M, Moritz T, Seeber S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8706-14.

Supplemental Content

Support Center